r84 dose in man in clinical trial in Russia

Affitech A/S 

20.08.2012 08:33

Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Release no. 22/2012

Copenhagen and Oslo, 20th August, 2012, 2012-08-20 08:33 CEST (GLOBE NEWSWIRE)
-- Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced
today that the first patient in the phase one clinical trial with Affitech's
anti-VEGF antibody AT001/r84 has been dosed. This open trial was approved by
the Russian authorities in March, 2012 followed by implementation of the first
clinical site in June, 2012. Enrollment and dosing of patients with AT001/r84,
which is being tested in Russia/CIS in patients with various metastatic
cancers, has started. 

AT001/r84 is a new patented fully human monoclonal antibody to human vascular
endothelial growth factor (VEGF), and is being developed as a potential
treatment of cancer. The anti-VEGF antibody is a possible competitor to
bevacizumab (Avastin(R) - Roche). 

Dr Alexander Duncan, Affitech's Chief Scientific Officer, said:

'AT001/r84 is a novel antibody drug which in disease models has proven to be a
potent and effective blocker of tumor vascularization and growth and we believe
it to have significant potential in the treatment of a number of different
human cancers. We are very pleased to see that the first patient in the phase
one trial with AT001/r84 has received the medicine and we look forward to the
result of this important study.' 

The clinical trial with AT001/r84 in Russia/CIS is conducted according to
international standards and the data generated will be useful for IBC Generium
to design further trials in Russia/CIS. 



About Affitech

Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company based in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The Company utilizes a range of proprietary antibody technologies for
the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS(TM) (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to
cell surface molecules. Affitech co-develops its two lead antibody drug
programs AT001/r84 and AT008/CCR4 with Russian partner IBC Generium. The
Company's initial focus is on rapid and cost effective development by
partnering clinical trials in emerging markets. Further information is
available at www.affitech.com. 



Disclaimer
This announcement may contain forward-looking statements including statements
about Affitech's expectations of the progression of its pipeline including the
timing for commencement and completion of clinical trials and with respect to
cash burn guidance. Such statements are based on Management's current
expectations and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those described in the
forward-looking statements. Affitech cautions investors that there can be no
assurance that actual results or business conditions will not differ materially
from those projected or suggested in such forward-looking statements as a
result of various factors, including, but not limited to, the following: risks
associated with technological development, the risk that research & development
will not yield new products that achieve commercial success, the impact of
competition, the ability to transact viable and profitable commercial deals,
the risk of non-approval of patents not yet granted, and difficulties of
obtaining relevant governmental approvals for new products. No expressed or
implied representations or warranties are given concerning Affitech A/S or the
accuracy or completeness of the information provided herein, and no claims
shall be made by the recipient of this news release by virtue of the
information contained herein. 


         Contact:
         
         Randi Krogsgaard, Director IR & Corporate Communications
         
         Tel # +45 2320 1001, e-mail: ir@affitech.com
News Source: NASDAQ OMX



20.08.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Affitech A/S
              
               
              Denmark
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         DK0015966592
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------

No Events found